BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Bioxytran Initiates University Of Georgia Collaboration Under 100 Million Dollar Grant To Target H5N1 Bird Flu

Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, announced it has initiated a research c...

February 24, 2026 | News

CStone Secures UK MHRA Approval For Sugemalimab In Stage III Non Small Cell Lung Cancer

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...

February 24, 2026 | News

Formosa Pharmaceuticals Signs Exclusive Licensing Agreement With Arrotex For APP13007 In Australia And New Zealand

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...

February 24, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

February 24, 2026 | News

Hansa Biopharma Announces FDA Acceptance of Imlifidase Biologics License Application

Hansa Biopharma AB, ("Hansa" or "the Company"), announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. F...

February 24, 2026 | News

NEXT Life Sciences Advances Two Non Hormonal Male Contraceptives Into Phase II Trials

Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest...

February 23, 2026 | News

YolTech Reports Positive Interim Data For YOLT 202 In Alpha 1 Antitrypsin Deficiency

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with ...

February 23, 2026 | News

Takeda Reports Positive Phase 3 KEPLER Data For ENTYVIO In Pediatric Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...

February 23, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...

February 23, 2026 | News

Deciphera Pharmaceuticals Secures FDA NDA Acceptance For Tirabrutinib In R R PCNSL

-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...

February 20, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

February 20, 2026 | News

Mammotome Introduces In Room MRI Guided Breast Biopsy System To Improve Clinical Workflow

Mammotome, a Danaher company, announces the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System, the industry's first system designed t...

February 19, 2026 | News

Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...

February 19, 2026 | News

Eli Lilly And Company Reports Statistically Significant Event Free Survival Benefit With Selpercatinib In Early Stage RET Fusion Positive NSCLC

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...

February 18, 2026 | News

Stay Connected